# Intravenous Ketamine for Treatment-Resistant Depression

> **NCT06668571** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 30 (estimated)

## Conditions studied

- Depressive Disorder, Treatment-Resistant
- Treatment Resistant Depression (TRD)

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT06668571
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06668571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06668571, "Intravenous Ketamine for Treatment-Resistant Depression". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06668571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*